Alpa Laboratories Ltd (ALPA) — shareholding pattern, promoter holding, financials and share price
About Alpa Laboratories Ltd (ALPA)
Alpa Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ALPA and on the BSE under scrip code 532878. Its ISIN is INE385I01010.
Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals [1]
Alpa Laboratories Limited is a pharmaceutical company established in 1988, specializing in the manufacture of pharmaceutical formulations across various dosage forms, including injectables, tablets, and creams.
The company serves a broad market, including ethical, generic, over-the-counter drugs, and veterinary products, with a marked presence in both domestic and international markets.
Listed peers in Pharmaceuticals: Panchsheel Organics Ltd, Auro Laboratories Ltd, Quest Laboratories Ltd, Natural Capsules Ltd, Kimia Biosciences Ltd, Smruthi Organics Ltd.
Valuation & Returns
10 Jul 2026At ₹68.78 a share on 10 Jul 2026, Alpa Laboratories Ltd (ALPA) was valued at a price-to-earnings ratio of 9.55x against an industry P/E of 36.41x and a price-to-book of 0.84x on a book value of ₹81.48 per share as of Mar 2025. Solomo computes return on equity of 8.84% and return on capital employed of 9.89% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 9.55x
- Industry P/E
- 36.41x
- P/B
- 0.84x
- EPS (TTM)
- ₹7.21
- Book value / share
- ₹81.48
- ROE
- 8.84%
- ROCE
- 9.89%
- ROA
- 6.81%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 18%
- 52-week range
- ₹46 – ₹106.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Alpa Laboratories Ltd (ALPA) reported revenue of ₹106 crore, net profit of ₹15 crore and earnings per share of ₹7.13. That compares with revenue of ₹110 crore and net profit of ₹20 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹31.4 crore and net profit ₹1.38 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 112 | 93 | 109 | 110 | 106 |
| Net profit (₹ cr) | 14 | 13 | 17 | 20 | 15 |
| EPS (₹) | 6.7 | 5.98 | 7.98 | 9.27 | 7.13 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.75% | 5.52% | 0.06% | 3.41% |
| Profit growth | 10.93% | 37.00% | 11.69% | 16.21% |
| Stock price CAGR | 9% | 7% | -1% | -33% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 57.19% of Alpa Laboratories Ltd (ALPA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.35% and domestic institutional investors (DII) hold 0.07%. Market capitalisation was ₹145 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2010.
Largest disclosed public shareholders in Jun 2026: HUF 1.25%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 57.19% | - | 0.35% | 0.07% | 42.81% |
| Mar 2026 | 57.19% | - | 0.38% | - | 42.81% |
| Dec 2025 | 57.29% | - | 0.36% | - | 42.71% |
| Sep 2025 | 57.29% | - | 0.35% | - | 42.71% |
| Jun 2025 | 57.29% | - | 0.36% | - | 42.71% |
| Mar 2025 | 57.29% | - | 0.4% | - | 42.71% |
| Dec 2024 | 57.29% | - | 0.35% | - | 42.71% |
| Sep 2024 | 57.29% | - | 0.74% | - | 42.71% |